Vertex Sells INCIVO ® Product Royalty Rights for $152 Million

  Vertex Sells INCIVO ® Product Royalty Rights for $152 Million

  -Vertex to receive $152 million cash payment from Janssen in 2013; will no
         longer receive royalties on INCIVO sales beginning in 2014-

   -Company increases 2013 year-end guidance for cash, cash equivalents and
             marketable securities to in excess of $1.4 billion-

Business Wire

CAMBRIDGE, Mass. -- November 20, 2013

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that it has
sold its product royalty rights relating to INCIVO^® (telaprevir) to Janssen
Pharmaceutica N.V. Under the agreement, Janssen will make a $152 million cash
payment to Vertex in the fourth quarter of 2013 and will cease paying
royalties to Vertex on INCIVO sales beginning in 2014.

"The monetization of INCIVO royalties provides cash to enhance our corporate
financial position and continues to position us to support our investment in
cystic fibrosis and to advance other key opportunities in our pipeline,” said
Ian Smith, Executive Vice President and Chief Financial Officer of Vertex.

As a result of the amendment to the companies’ 2006 collaboration agreement to
develop and commercialize INCIVO in Europe and other regions, Janssen will
have sole authority to execute INCIVO marketing and promotion activities in
these regions. Ongoing studies will be completed as planned, and the amended
agreement accounts for this more streamlined collaboration.

Vertex also today increased its 2013 year-end guidance for cash, cash
equivalents and marketable securities to in excess of $1.4 billion.

About Vertex

Vertex is a global biotechnology company that aims to discover, develop and
commercialize innovative medicines so people with serious diseases can lead
better lives. Vertex scientists and our collaborators are working on new
medicines to cure or significantly advance the treatment of cystic fibrosis,
hepatitis C, rheumatoid arthritis and other life-threatening diseases. In
addition to our clinical development programs, Vertex has more than a dozen
ongoing preclinical programs aimed at other serious and life-threatening
diseases.

Founded in 1989 in Cambridge, Mass., Vertex today has research and development
sites and commercial offices in the United States, Europe, Canada and
Australia. For four years in a row, Science magazine has named Vertex one of
its Top Employers in the life sciences. For additional information and the
latest updates from the company, please visit www.vrtx.com.

Indication and Important Safety Information for INCIVEK (telaprevir)

INCIVEK® (telaprevir) is a prescription medicine used with the medicines
peginterferon alfa and ribavirin to treat chronic (lasting a long time)
hepatitis C genotype 1 infection in adults with stable liver problems, who
have not been treated before or who have failed previous treatment. It is not
known if INCIVEK is safe and effective in children under 18 years of age.

Important Safety Information

INCIVEK® (telaprevir) should always be used in combination with peginterferon
alfa and ribavirin. INCIVEK combination treatment may cause serious side
effects including skin rash and serious skin reactions, anemia (low red blood
cell count) that can be severe, and birth defects or death of an unborn baby.

Skin rashes are common with INCIVEK combination treatment. Sometimes these
skin rashes and other skin reactions can become serious, require treatment in
a hospital, and may lead to death. Patients should call their healthcare
provider right away if they develop any skin changes or itching during
treatment with INCIVEK. Their healthcare provider will decide if they need
treatment or if they need to stop INCIVEK or any of their other medicines.
Patients should not stop taking INCIVEK combination treatment without talking
with their healthcare provider first.

Patients' healthcare providers will do blood tests regularly to check for
anemia. If anemia is severe, the healthcare providers may tell them to stop
taking INCIVEK.

INCIVEK combined with peginterferon alfa and ribavirin may cause birth defects
or death of an unborn baby. Therefore, a patient should not take INCIVEK
combination treatment if she is pregnant or may become pregnant, or if he is a
man with a sexual partner who is pregnant. Females who can become pregnant and
females whose male partner takes these medicines must have a negative
pregnancy test before starting treatment, every month during treatment, and
for 6 months after treatment ends. Patients must use two forms of effective
birth control during treatment and for 6 months after all treatment has ended.
These two forms of birth control should not contain hormones, as these may not
work during treatment with INCIVEK.

INCIVEK and other medicines can affect each other and can also cause side
effects that can be serious or life-threatening. There are certain medicines
patients cannot take with INCIVEK combination treatment. Patients should tell
their healthcare providers about all the medicines they take, including
prescription and over-the-counter medicines, vitamins and herbal supplements.

The most common side effects of INCIVEK combination treatment include itching,
nausea, diarrhea, vomiting, anal or rectal problems (including hemorrhoids,
discomfort, burning or itching around or near the anus), taste changes and
tiredness. There are other possible side effects of INCIVEK, and side effects
associated with peginterferon alfa and ribavirin also apply to INCIVEK
combination treatment. Patients should tell their healthcare provider about
any side effect that bothers them or doesn't go away.

Please see full Prescribing Information including Boxed Warning, and the
Medication Guide for INCIVEK available at www.INCIVEK.com.

Vertex Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, including, without
limitation, Mr. Smith’s statements in the second paragraph of the press
release and statements regarding the company’s expectations regarding its 2013
year-end cash position. While Vertex believes the forward-looking statements
contained in this press release are accurate, those statements are subject to
risks and uncertainties that could cause actual outcomes to vary materially
from the outcomes referenced in the forward-looking statements. These risks
and uncertainties include, among other things, that the company’s expectations
regarding its year-end 2013 cash position may be incorrect and the other risks
listed under Risk Factors in Vertex's annual report and quarterly reports
filed with theSecurities and Exchange Commissionand available through the
company's website atwww.vrtx.com. Vertex disclaims any obligation to update
the information contained in this press release as new information becomes
available.

VRTX – GEN

Contact:

Vertex Contacts:
Media:
Zach Barber, 617-341-6992
mediainfo@vrtx.com
or
Investors:
Michael Partridge, 617-341-6108
or
Kelly Lewis, 617-961-7530
 
Press spacebar to pause and continue. Press esc to stop.